Internal Medicine, Endocrinology, Diabetes, & Metabolism · Lubbock, TX
NPI
1477611044
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
0
Medicare group memberships
Hospitals
5
Hospital affiliations
2716 82nd St
Lubbock, TX, 79423
Phone (806) 793-4440
Medicare paid, 2024
$69K
2,400 services
Medicare patients, 2024
481
Average age 74
Drug cost, 2024
$2.4M
8,365 prescriptions
Company payments, 2025
$1,098
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael R Macadams was code 99213 (office e&m - established), 803 times for 374 patients. In total Michael R Macadams billed 2,400 services in 13 codes, and Medicare paid $69K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-03-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 803 | 374 | $53.32 | $43K |
| 83036 Blood Count | Office | 642 | 267 | $9.24 | $5,931 |
| 82947 Clinical Chemistry | Office | 409 | 222 | $3.67 | $1,503 |
| 95251 Test - Miscellaneous | Office | 280 | 108 | $21.97 | $6,153 |
| 99212 Office E&M - Established | Office | 122 | 107 | $30.04 | $3,665 |
| 99214 Office E&M - Established | Office | 61 | 53 | $78.24 | $4,773 |
| 99204 Office E&M - New | Office | 22 | 22 | $97.97 | $2,155 |
| 99203 Office E&M - New | Office | 22 | 22 | $65.64 | $1,444 |
| 95249 Test - Miscellaneous | Office | 12 | 12 | $36.46 | $438 |
| 99211 Office E&M - Established | Office | 11 | 11 | $15.89 | $175 |
By year: 2022 $97K for 3,079 services; 2023 $95K for 3,015 services; 2024 $69K for 2,400 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 642 | 267 | $9.24 | $5,931 |
| 82947 Clinical Chemistry | 409 | 222 | $3.67 | $1,503 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael R Macadams prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,436 prescriptions and refills. In total Michael R Macadams wrote 8,365 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,436 | 3,563 | 339 | $14K |
| Metformin Hcl Generic | 509 | 1,465 | 160 | $4,585 |
| Ozempic Semaglutide | 362 | 582 | 82 | $537K |
| Glipizide Generic | 265 | 661 | 81 | $2,389 |
| Synthroid Levothyroxine Sodium | 264 | 571 | 60 | $17K |
| Glimepiride Generic | 255 | 711 | 70 | $2,146 |
| Jardiance Empagliflozin | 215 | 483 | 57 | $280K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 195 | 536 | 66 | $38K |
| Mounjaro Tirzepatide | 185 | 251 | 40 | $260K |
| Rosuvastatin Calcium Generic | 184 | 466 | 52 | $2,374 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 167 | 433 | 78 | $21K |
| Atorvastatin Calcium Generic | 153 | 441 | 45 | $1,063 |
| Methimazole Generic | 149 | 423 | 51 | $2,071 |
| Januvia Sitagliptin Phosphate | 149 | 287 | 40 | $153K |
| Amlodipine Besylate Generic | 149 | 432 | 47 | $1,006 |
Brand drugs: 3,252 claims; generic drugs: 4,645 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael R Macadams $1,098 ($1,098 in general payments such as food, travel and fees) from 14 companies. The largest payer was Novo Nordisk Inc with $244.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 17 | $244 |
| Abbott Laboratories ABT | 20 | $191 |
| Corcept Therapeutics CORT | 9 | $175 |
| Mannkind Corporation MNKD | 3 | $105 |
| Sequel Med Tech, LLC | 1 | $82.48 |
| Amgen Inc. AMGN | 3 | $71.87 |
| Lilly USA, LLC LLY | 3 | $59.46 |
| Tandem Diabetes Care, Inc. TNDM | 2 | $35.25 |
| Madrigal Pharmaceuticals MDGL | 1 | $30.63 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $25.65 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.